Objectives: Francisella tularensis, a CDC class A potential bioterrorism agent, is a Gram-negative bacterium responsible for tularaemia. Understanding the mechanisms of resistance to antibiotics used as first-line treatment is of major security relevance.
Introduction
Francisella tularensis is a Gram-negative facultative intracellular bacterium, which causes the life-threatening zoonosis tularaemia. 1 Two subspecies are responsible for human tularaemia: F. tularensis subsp. tularensis (type A) in North America 2 and F. tularensis subsp. holarctica (type B) in the entire northern hemisphere. The latter subspecies includes the two biovars: I (naturally susceptible to macrolides) in Western Europe and North America; and II (naturally resistant to macrolides) in Eastern Europe and Asia. 3 F. tularensis is a CDC Category A bioterrorism agent, 4 especially because of its very high infectiousness. 5 Dissemination of an infectious aerosol in a human population may cause many pneumonic cases, with mortality rates as high as 60% for the more virulent type A strains. 6 A live vaccine strain (LVS) of F. tularensis subsp. holarctica has been used for prophylaxis of tularaemia, especially for laboratory workers. 6 It is, however, no longer used because of limited efficacy 7 and concerns about the possibility of reversion to virulence. 8 No other vaccine is currently available for human use. Antibiotics are effective in treating tularaemia patients and represent the main counter-measure in the context of biological threat. The aminoglycosides streptomycin and more recently gentamicin are considered to be the reference treatment. 9, 10 Because of their side effects, especially nephrotoxicityand ototoxicity, their use is currently restricted to severe tularaemia cases. The fluoroquinolones and tetracyclines, especially ciprofloxacin and doxycycline, respectively, are advocated as first-line drugs for patients with diseases of mild to moderate severity. 9, 10 However, treatment failures and relapses occur in 10%-15% of patients treated with a fluoroquinolone 11, 12 and even more frequently when a tetracycline is administered. 10 Treatment failures and relapses are considered to be independent of the acquisition of antibiotic resistance in F. tularensis, mainly because no strains with acquired resistance to first-line antibiotics have been isolated so far. 13 However, acquired resistance to fluoroquinolones has emerged in many bacterial species, 14 -16 and difficulties in isolating F. tularensis from clinical samples may preclude the detection of antibiotic-resistant mutants. Mutants resistant to fluoroquinolones have been selected in vitro from the type A Schu4 strain 17 and to fluoroquinolones 18 and macrolides 19 from type B strains. Antibiotic resistances resulted from target modifications, but only few mutations were identified in the topoisomeraseencoding genes gyrA and parE 17, 18 for fluoroquinolones and in the ribosomal genes rrl and rplV for macrolides. 19 More detailed information is therefore required about the antibiotic resistance mechanisms, but also on the evolutionary pathways leading to high-level resistance in F. tularensis. Such results will optimize resistance detection and therefore antibiotic treatment of tularaemia patients. Moreover, a rapid DNA-based assay would be essential in the context of a biological threat related to the use of antibiotic-resistant F. tularensis strains.
Here, we show that high-level fluoroquinolone-resistant mutants can be easily and quickly obtained from diverse Francisella species strains after propagation with increasing antibiotic doses. We characterized the phenotypic and genetic evolutionary pathways from low to high resistance levels. Strikingly, these evolutionary pathways resulted in threatening cross-resistances to other antibiotic families.
Materials and methods

Bacterial strains and culture media
Three reference strains of Francisella species were used: F. tularensis subsp. holarctica LVS NCTC 10857 (a gift from Emile Pardé Research Center, Institut de Recherche Biomédicale des Armées, Grenoble, France), F. novicida CIP56.12 [Centre de Ressources Biologiques de l'Institut Pasteur (CRBIP), Institut Pasteur, Paris, France] and F. philomiragia ATCC 25015 (CRBIP). These strains were chosen to increase the likelihood of identifying different types of fluoroquinolone resistance mechanisms in Francisella, and for safety reasons related to their attenuated virulence in humans. We used Escherichia coli ATCC 25922, Enterococcus faecalis ATCC 29212 and Pseudomonas aeruginosa ATCC 27853 (CRBIP) as control strains for the determination of MICs. All experiments were conducted in a biosafety level 3 laboratory.
Francisella strains were grown on Polyvitex-enriched chocolate agar (PVX-CHA) plates (bioMérieux, Marcy l'Étoile, France) that were incubated at 378C in a 5% CO 2 -enriched atmosphere for 48 -72 h. Selection of fluoroquinolone-resistant mutants and MIC determination were performed using liquid MHPV medium, consisting of Mueller-Hinton broth (AES, Bruz, France) supplemented with 2% Polyvitex (bioMérieux). Control strains were grown on 5% sheep blood-enriched Columbia agar (COS) plates (bioMérieux), which were incubated in the same conditions for 24 h.
Selection and sampling of ciprofloxacin-resistant mutants
Four independent lineages were founded using each of the three antibioticsusceptible reference Francisella strains. We named each lineage after the species of its corresponding parental strain (Fth for F. tularensis subsp. holarctica, Fno for F. novicida and Fph for F. philomiragia), followed by an arbitrary number (1 -4) denoting each of the four individual lineages. For example, Fno1 is the first of the four lineages propagated from F. novicida. Owing to growth difficulties during the propagation of one lineage derived from F. tularensis subsp. holarctica, only three lineages could be obtained with this strain, Fth1 to Fth3. Therefore, a total of 11 lineages were started and propagated by serial passages in MHPV medium supplemented with increasing concentrations of ciprofloxacin (Mylan, Saint Priest, France; Sigma-Aldrich, Saint-Quentin Fallavier, France; and Panpharma, Fougères, France) as described previously. 19 Briefly, increasing 2-fold serial concentrations of ciprofloxacin (in MHPV) were added volume-to-volume to bacterial suspensions containing 10 7 cells/mL, resulting in final ciprofloxacin concentrations from 0.5-to 64-fold the MIC for the parental strain. After 3 -5 days incubation at 378C in a 5% CO 2 -enriched atmosphere, the lowest concentration of ciprofloxacin inhibiting bacterial growth was recorded for each lineage. This procedure constituted the first selection passage. This concentration, denoted MICp, measures the MIC of ciprofloxacin for the entire cell population, which may be heterogeneous and contain different mutants. For each lineage, the bacterial population present in the well with a ciprofloxacin concentration of MICp/2 was diluted 10-fold in MHPV into new wells that contained 2-fold serial concentrations of ciprofloxacin (0.5-to 64-fold the MICp for the previous passage). A total of 14 selection passages were performed, resulting in MICp ranging from 512 to 4096 times the ciprofloxacin MIC for the parental susceptible strains. At each selection passage, a sample of the MICp/2 bacterial population from each of the 11 lineages was collected and frozen in cryotubes at 2808C. A growth control (no antibiotic) and a negative control (only MHPV) were prepared at each selection passage.
To isolate individual resistant clones, the frozen mixed-lineage samples were plated on PVX-CHA medium and incubated for 2 -5 days at 378C. Individual colonies, each representing a single resistant clone, were picked, subsequently grown on PVX-CHA medium and stored at 2808C. This sampling procedure was performed to isolate one high-level resistant mutant from each lineage after the final (14th) selection passage and a total of 52 clones at intermediate selection passages (see Figure 1 ). Sampling times were either distributed along the evolutionary pathways of a lineage or corresponded to passages showing a significant (≥4-fold) increase in the MICp of ciprofloxacin. We named each of the evolved highlevel resistant clones after its lineage, followed by P14. For example, Fth1P14 is the clone sampled from lineage 1 of F. tularensis subsp. holarctica LVS at passage P14, the final passage.
MIC determination
We determined the MICs of ciprofloxacin, levofloxacin (Sigma-Aldrich) and moxifloxacin (Bayer, Loos, France) to evaluate the impact of the mutations we identified on fluoroquinolones of different generations. We also determined the MICs of gentamicin (Panpharma), doxycycline (Sigma-Aldrich) and erythromycin (Sigma-Aldrich) to evaluate cross-resistance. Indeed, aminoglycosides and tetracyclines are used in the treatment of tularaemia, and resistance to erythromycin frequently involves changes in efflux systems resulting in multidrug resistance. Antibiotic stock solutions were prepared according to the manufacturers' instructions and stored at 2808C. The MICs were determined using a microdilution method in MHPV, as recommended by CLSI. 20 For each antibiotic, 2-fold serial concentrations in MHPV were distributed (75 mL per well) in 96-well microtitre plates (Becton Dickinson), and an equal volume of a bacterial suspension containing 10 6 cells/mL prepared in MHPV was added to each well. The plates were incubated at 378C for 48 h in a 5% CO 2 -enriched atmosphere. The lowest antibiotic concentration inhibiting bacterial growth was recorded as the MIC. All experiments were performed in duplicate. For each experiment, a growth control (no antibiotic), a negative control (MHPV with the lowest antibiotic concentration tested, without bacterial cells) and the three control strains (see above) were performed in parallel.
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Sequencing the type II topoisomerase-encoding genes
Bacterial cells were grown at 378C for 2-5 days on PVX-CHA plates from which colonies were harvested and resuspended in sterile water. Genomic DNA was extracted using the QiaAmp DNA Minikit (Qiagen, Courtaboeuf, France). The PCR reactions were performed using the Pwo Master kit (Roche Applied Science, Meylan, France). Primers (Table S1 , available as Supplementary data at JAC Online) were designed based on the available genome sequences of F. tularensis subsp. holarctica LVS (NC_007880), F. novicida U112 (NC_008601) and F. philomiragia ATCC 25017 (NC_ 010336). Five, four, four and three primer pairs were designed to amplify the four genes gyrA, gyrB, parC and parE, respectively, each primer pair allowing the amplification of 507-800 bp regions of each gene, including their quinolone resistance-determining regions (QRDRs). The PCR reactions, containing 0.4 mM of each primer and 2 ng/mL genomic DNA, were optimized for annealing temperatures and cycle numbers for each primer pair and Francisella strain. All PCR products were sequenced in the high-level resistant clones isolated after the final (14th) passage in each of the 11 lineages, while only the PCR products corresponding to the regions carrying mutations were sequenced in the 52 evolved clones sampled at intermediate selection passages. Sequencing was performed using the same primers and the dye terminator method, with the DTCS Quick Start Kit (Beckman Coulter, Villepinte, France) on a Ceq 8000 sequencer (Beckman Coulter). Sequence alignments were performed using Ceq 8000 software (Beckman Coulter).
Mapping resistance mutations on three-dimensional topoisomerase structures
Sequences were retrieved and aligned using tools from the NPS@ web site. 21 The effect of deletion alleles was analysed using SwissModel. 22 Structures were analysed and illustrations generated using PyMOL (www.pymol.org). The DNA gyrase mutations were analysed using the structure of an engineered GyrAB construct from Staphylococcus aureus complexed with DNA and ciprofloxacin (pdb entry 2XCT), 23 and the topoisomerase IV mutations using the structure of an engineered ParCE construct from Streptococcus pneumoniae complexed with DNA and moxifloxacin (pdb entry 3FOF). 24 The amino acid sequence identity of S. aureus GyrAB and S. pneumoniae ParCE with the corresponding Francisella proteins is 55% and 35%, respectively.
Results
Selection of ciprofloxacin-resistant mutants from three low-virulence Francisella strains
We first determined the MICs of ciprofloxacin for each of the three Francisella species parental strains that we used to propagate the 11 lineages. These MICs were 0.016, 0.064 and 0.032 mg/L for F. tularensis subsp. holarctica LVS, F. novicida and F. philomiragia, respectively. In all lineages, the 14 selective passages resulted in high resistance levels, with measured ciprofloxacin concentrations inhibiting growth (MICp) between 16 and 128 mg/L ( Figure 1 ). These MICp values were obtained for the mixed populations after P14. Two types of evolutionary trajectories towards high resistance levels were observed in the 11 lineages ( Figure 1 ): one showed gradual increases in the ciprofloxacin MICps by 2-to 4-fold incremental steps, and one showed steeper variations in the MICps, including 8-to 32-fold incremental steps. All four Fno-derived lineages revealed a gradual trajectory type, while the three Fthand four Fph-derived lineages showed steep steps along their respective evolutionary pathways. These data suggested evolution towards high resistance through the successive substitution of resistance mutations conferring increasingly high resistance levels. Moreover, each steep step may be conferred by either several mutations occurring over a single passage or a single mutation with stronger impact on MIC. To get insights into the mechanistic details of increased resistance levels, we sampled not only one evolved clone from each of the 11 lineages at the final passage (P14), but also 52 clones from intermediate passages in the three lineages derived from F. tularensis subsp. holarctica LVS (Figure 1 ). Fluoroquinolone resistance in Francisella species 103 
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Resistance phenotypes of parental strains and evolved mutants
We determined the MICs of several antibiotics for the parental susceptible strains and the high-level resistant clones sampled at the final passage from each of the 11 lineages (Table 1) : the fluoroquinolones ciprofloxacin (the selection agent), levofloxacin and moxifloxacin; the aminoglycoside gentamicin; the macrolide erythromycin; and doxycycline, a tetracycline compound. All three parental strains showed low MIC values, except for the well-known natural resistance to macrolides of the Fth strain 25 and, to a lesser extent, the Fno and Fph strains.
As expected from the selection procedure, all evolved clones displayed high levels of resistance to ciprofloxacin, with 512-to 2048-fold increases in the MIC values (Table 1 ). We observed crossresistance to the two other fluoroquinolones, with similar increases in MICs. All evolved clones revealed moderate (2-to 8-fold) increases in doxycycline MICs, with the highest levels observed in the Fno-derived clones. We also observed a further increase in the erythromycin MICs for the Fno-and Fph-derived clones, with Fno2P14 and Fno4P14 displaying high-level resistance (MIC ≥256 mg/L). Finally, the MIC profiles of gentamicin were more surprising and were different for the three parental strains (Table 1) . Hence, we observed decreases in the gentamicin MICs for more than half of the evolved clones (seven) compared with their respective parental strains, by 2-to 4-fold for Fno1P14, Fno2P14 and Fno3P14, and 4-to 32-fold for the four Fph-derived clones (Table 1) . By contrast, a 4-fold increase in the gentamicin MIC was observed for clone Fno4P14 while no change was detected for Fth1P14, Fth2P14 and Fth3P14.
Mapping resistance mutations on the three-dimensional structures of topoisomerases
We identified a total of 26 mutations affecting the type II topoisomerase-encoding genes in the 11 high-level resistant mutants isolated after P14 in each lineage (Table 1) , and located these mutations on the three-dimensional structure of topoisomerases ( Figure 2 ). Twenty-two mutations resulted in changes in the GyrAB proteins and four in ParCE changes. Three mutations were identified in each of the three Fth-derived clones, in one Fno-and two Fph-derived clones, while we found two mutations in another Fno-derived and the other two Fph-derived clones, and only one in the two last Fno-derived clones. These results suggested that mutations also occurred in some other genes not encoding type II topoisomerases (see next section). Most mutations in gyrA (10/13) affected codons 83 and 87, located in the QRDR (Table 1 and Figure 2a ). These mutations were located next to the carboxylate group of fluoroquinolones (see Discussion) and resulted in significant increases in MICs. 23 One-third of the mutations in gyrB (3/9, in two Fth-derived clones and one Fnoderived clone) affected codons 464 -466, changes in which had been previously shown to be associated with fluoroquinolone resistance in E. coli. 26 The affected residues in the GyrB protein were close to the fluoroquinolone intercalation site (Figure 2a ) and had smaller effects on MICs. 23, 24 Nine mutations, three in gyrA and six in gyrB, were located outside the defined QRDRs. The P43H change in GyrA was located in a region of the protein that likely interacts with DNA (Figure 2a) . The in-frame DE523 -S524 change in GyrA affected the surface of the GyrAB -DNA complex as was the case for the D486E -DK487 change in GyrB (Figure 2a) . The unusual P747S change in GyrB was found in all Fph-derived clones, this residue being located close to the bound DNA and the intercalated fluoroquinolone. The last two changes, DT570 in GyrA and E86K in GyrB, could not be mapped as they occurred outside the catalytic core of the enzyme. The E86K change might have no effect on fluoroquinolone resistance as this position is variable across bacterial species.
The mutational pattern in parC and parE (Table 1) revealed that only one of four mutations, resulting in the DC82 change in ParC, was located in the QRDR (Figure 2b) . The other mutation affecting parC resulted in the introduction of a stop codon at position 453 that most likely destabilized the overall structure of the topoisomerase IV and abolished its activity. We indeed observed a highly reduced growth rate of this particular mutant, Fth2P14, in the absence of antibiotic (data not shown). The P472S change in ParE was located at the surface of the ParCE-DNA complex in a loop similar to the one that carries the D486E -DK487 GyrB change (Figure 2b ). It might therefore have a similar effect. We were unable to predict the effect of the rather conservative L488I substitution within the hydrophobic core of parE.
Phenotypic and genotypic evolution of resistance lineages
The study of frozen bacterial populations, obtained at different stages of selection of ciprofloxacin resistance, allowed us to characterize the evolutionary trajectories towards high-level resistance to this antibiotic in the three lineages Fth1, Fth2 and Fth3 (Figure 3) . After plating the frozen mixed-lineage samples from several selection passages we isolated 52 individual clones (Figure 1 ), for which we determined the MIC of ciprofloxacin. We scored these 52 clones for the presence or absence of mutations affecting the type II topoisomerase-encoding genes that we found in the high-level resistant mutants from the corresponding lineages. Four main trends emerged from these data (Figure 3) .
First, the MIC of ciprofloxacin for the different individual clones confirmed the progressive increase in the fluoroquinolone resistance levels, indicative of the substitution of successive resistance mutations in the different lineages. Moreover, steep steps of MIC increase were observed, as observed for MICp, in all three lineages (Figures 1 and 3) . However, discrepancies were apparent at given passages between the MICp for the entire population (Figure 1 ) and the MICs for individual clones (Figure 3 ). For example, the MICp for Fth1 at P4 increased by 8-fold compared with the MIC for the parental susceptible strain, whereas a 256-fold increase was measured for an individual clone sampled at that time. These differences may indicate polymorphic states of the corresponding population during the different passages (see below).
Second, our sampling procedure allowed identification of the order of substitution of different mutations resulting in high resistance levels (Figure 3 ). The first genetic change detected in all three of the lineages Fth1 -Fth3 targeted the DNA gyrase-encoding genes through a mutation either in codon 83 of gyrA (gyrA 83 , Fth2 and Fth3) or in the codon 466 of gyrB (gyrB 466 , Fth1). These mutations were subsequently shared by all descendant clones studied in their respective lineage. The second change in Fth1 also affected DNA gyrase through a gyrA 83 mutation, while the third mutation occurred at codon 488 of parE. Considering lineage Fth3, the second change occurred in parC 82 , followed by a third change in gyrB 464 . In lineage Fth2, the final P14-sampled Sutera et al. clone also carried three mutations. After the first gyrA 83 mutation in Fth2, two others occurred in gyrA 87 and parC 453 , but their precise order of substitution is unknown (Figure 3) .
Third, genetic and phenotypic polymorphisms were detected in the two lineages Fth1 and Fth3. Indeed, several passages were characterized by the co-existence of different resistant clones (Figure 3) , some of which went extinct without leaving progeny during the later evolutionary steps (at least at our detection level). This was the case at P10 in lineage Fth1, where three different types of resistant clones with different mutations co-existed, with similar resistance levels ( Figure 3 ). This suggests different genetic pathways towards ciprofloxacin resistance. In addition, we detected a polymorphism at P12 in lineage Fth3. Indeed, three types of clones with only the gyrA 83 mutation had three different MIC values (Figure 3 ). These findings emphasize the presence of additional mutations targeting other resistance mechanisms (see below). The sub-population dynamics fitted well with the values of the MIC of ciprofloxacin. Hence, the winning clones that eventually took over the population in lineage Fth3 emerged from the sub-lineage that had the highest MIC at the polymorphic P12 (Figure 3) .
Fourth, by focusing on the known genetic targets of fluoroquinolones we evidently missed mutations that occurred during evolution towards high levels of resistance. Three lines of evidence suggested that gyrase and topoisomerase IV were not the only targets of selection during our experiment. Indeed, different resistant clones with the same genotype for the topoisomerase-encoding genes had different MICvalues. This was the case for clones sampled from the same passage as at P12 in Fth3 (see above and Figure 3 ), but also across evolutionary passages while the MIC was increasing (in Fth1 from P4 to P8, and in Fth3 from P2 to P12). Moreover, we found cross-resistance to other antibiotic classes in the Fno-and Fph-derived lineages that could not be explained by the type II topoisomerase mutations. Finally, we detected only a single gyrA mutation in the resistant clones sampled at the final passage (P14) for lineages Fno3 and Fno4 ( Table 1 ), suggesting that the same was true for these Fno-derived lineages.
Discussion
We investigated the evolutionary pathways towards high-level fluoroquinolone resistance in three different Francisella species by in vitro exposure of the parental susceptible strains to increasing concentrations of ciprofloxacin. By focusing on the known targets of fluoroquinolones, we identified mutations in the QRDR of type II topoisomerases that were already known to be associated with increased resistance, 26 but also previously uncharacterized changes both outside the QRDR of gyrA and parC and in unusual genetic regions of gyrB. Moreover, cross-resistance to gentamicin and doxycycline, which are commonly used in the treatment of tularaemia, was detected. The evolutionary pathways towards highlevel resistance were characterized at one extreme by a high level of genetic parallelism, with the same genes, and sometimes even the same codons, being altered by mutations among replicate lineages of the same and even different parental strains, and at the other extreme by lineage specificity at either the allelic level or the order of mutations. We also detected a high level of diversity with several genetically differentiated sub-populations co-existing at given evolutionary times.
The two major mechanisms of fluoroquinolone resistance are mutations in either genes gyrAB and parCE, encoding the targets of fluoroquinolones, or genes leading to overexpression of efflux pumps. 26 We focused here on the first type of mutation. 27 In Gramnegative bacteria, GyrA is usually the major target of fluoroquinolones, and gyrA mutations often correspond to the first step towards high-level resistance. They mostly occur in the QRDR of E. coli GyrA. 28 Codons 83 and 87 are the main targets of mutations (Table 1) is shown in violet at the back of the model. in many bacteria, including E. coli, 15 Pseudomonas aeruginosa 16 and Legionella pneumophila. 14 Mutations of codons 83 and 87 are associated with 4-to 32-fold and 1-to 4-fold increases in fluoroquinolone MICs, respectively, 26 including in clinical isolates of several Gram-negative species. 29 Resistance levels to fluoroquinolones may be further increased by additional mutations in gyrA, gyrB, parC and parE. 14, 26, 28 In contrast to gyrA, resistance-associated mutations in gyrB, parCand parE present higher variability in position, nature and simultaneous presence of mutations in other genes. 26 In vitro high-level resistance to fluoroquinolones has previously been reported in F. tularensis subsp. tularensis and subsp. holarctica.
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A gyrA 83 mutation leading to a T83I change was detected in both strains while additional mutations occurred for F. tularensis subsp. tularensis in gyrA (D87Y) and parE (5 bp deletion). The gyrA 83 and gyrA 87 mutations were associated with fluoroquinolone resistance.
However, in both studies, only one clone was analysed and evolutionary pathways towards high resistance, precise resistance levels to fluoroquinolones and cross-resistance to other antibiotic classes were not addressed. Our study not only extends the data available for Francisella species, but also provides new results compared with other Gramnegative bacteria. We found mutations in type II topoisomeraseencoding genes that have been already detected in many bacteria, 14 -16,26 and we also identified mutations ( Table 1 ) that have not previously been reported, or have only rarely been reported, to be associated with fluoroquinolone resistance phenotypes. For example, Fno3P14, Fno4P14 and Fph4P14 harboured mutations outside the QRDR of gyrA resulting, respectively, in the in-frame deletion of both codons 523 and 524, in the change in codon 43 and in the in-frame deletion of codon 570. Resistance mutations outside holarctica LVS strain. The genotypes for gyrA, gyrB, parC and parE and the MIC of ciprofloxacin (both in mg/L and as fold increase compared with the LVS susceptible strain) are indicated for all sampled resistant clones. For each gene, the codon affected by mutations is given (e.g. the gyrA 83 mutation resulted in the change in codon 83), the precise nucleotide changes being described in Table 1 . In a given lineage, the nucleotide changes affecting a given codon at intermediate passages are identical to those identified at P14. In one case (*) we identified a mutation (DA1366 in parE, resulting in the introduction of a stop codon at position 456 of the ParE protein) that was not present in the resistant clone at the final passage. The proportion of each particular genotype found at a given passage is indicated in parentheses. When a high level of polymorphism was detected, all genotypes observed at a given passage are grouped inside a black box. A total of 52 individual clones were isolated at intermediate passages ( Figure 1 ): 1 clone at each of P3, P4, P5 and P8, and 20 clones at P10 for Fth1, corresponding to 4-, 8-, 256-, 512-and 1024-fold increases in MICp, respectively; 1 clone at each of P2, P5, P7 and P8 for Fth2, corresponding to 64-, 128-, 512-and 1024-fold increases in MICp, respectively; and 1 clone at each of P2, P5, P9, P11 and P13, and 19 clones at P12 for Fth3, corresponding to 64-and 128-fold increases in MICp for P2 and P5, respectively, to 512-fold increases for P9, P11 and P12, and to a 2048-fold increase for P13.
Fluoroquinolone resistance in Francisella species the QRDR of gyrA have only rarely been reported (at codon 196 in E. coli and codons 119, 131, 139 and 144 in Salmonella enterica). 15 We found a similar situation for the gyrB mutations affecting codons 86 and 747 in the Fph lineages and for the nonsense mutation in parC in the lineage Fth2 (Table 1) . Moreover, other mutations, even if localized in the well-known QRDRs, resulted in unusual alleles, such as GyrA DT83 in Fph3P14 and ParC DC82 in Fth3P14. We mapped all mutations in the structure of the corresponding proteins complexed with DNA and antibiotics ( Figure 2 ). All point mutations that occurred in the QRDR of the type II topoisomerases are likely to interfere with the carboxylate group of fluoroquinolones. Moreover, our molecular modelling analyses suggest that deletion alleles between positions 83 and 87 in the gyrA gene are likely to move the negatively charged residue 87 towards the carboxylate group of the fluoroquinolone, introducing an unfavourable interaction. This may explain the effect of the GyrA DT83 change in Fph3P14 and, by analogy, the ParC DC82 change in Fth3P14. Residues 464-466 in GyrB, which were altered by mutations, are located close to both the intercalated fluoroquinolone and the DNA substrate, thereby probably influencing fluoroquinolone or DNA binding. 30 The P747S change in GyrB is also located close to the bound fluoroquinolone and DNA. The increased flexibility resulting from the proline change may result in structural rearrangements influencing fluoroquinolone binding. Interestingly, the residues following the position corresponding to Pro747 are disordered in the ParE structure. The mutation resulting in the P43H change in GyrA also likely affects DNA binding. Moreover, the mutations producing the DE523-S524 and DT570 changes in GyrA and the D486E-DK487 change in GyrB rather act on the position of domains of the complexes that are absent from the crystal structure or affect additional interactions with DNA that are required for DNA gyrase activity. 31, 32 The implication of the E86K GyrB change in fluoroquinolone resistance remains uncertain as it affects a variable residue. Finally, two frame-shift mutations in ParC and ParE, one in the high-level resistant clone isolated at the final passage in lineage Fth2 and one in an intermediate clone isolated at P10 of Fth1, resulted in a truncated, thereby likely non-functional, topoisomerase IV protein. Construction and phenotypic analyses of isogenic strains with and without these mutations in the genome of the susceptible parental strains will help to measure their effect on fluoroquinolone resistance.
Striking cross-resistance profiles were detected for the fluoroquinolone-resistant mutants derived from F. novicida and F. philomiragia, including significant increases in the MICs of doxycycline and erythromycin, and more surprisingly decreases in the MIC of gentamicin. These data suggest additional resistance mechanisms, either overexpression of efflux pumps that are known to confer multidrug resistance 33 or regulatory changes. Moreover, no obvious changes in the pH of the cultures, which have been shown to affect susceptibility levels to tetracyclines and aminoglycosides, 34 were observed during the experiments (data not shown). Gentamicin MICs determined in parallel for the control strains were in the expected range. The evolutionary pathways of the different Francisella lineages also emphasize that we did not detect all mutations leading to high levels of fluoroquinolone resistance. Indeed, different MIC values were sometimes measured for genotypes identical for the type II topoisomeraseencoding genes that were sampled from the same passages within a given lineage, while increasing MICvalues were sometimes measured for clones with the same genotypes for topoisomeraseencoding genes that were sampled over many passages within a given lineage (Figure 3) . Moreover, in the case of F. novicida, we detected a single mutation in gyrA in two final high-level resistant mutants that is unlikely to explain on its own the MIC increases. Only one previous study described the presence of an efflux pump in the LVS strain of F. tularensis subsp. holarctica. This efflux pump belongs to the resistance nodulation division (RND) family and is involved in virulence and multidrug resistance, including resistance to b-lactams, rifampicin and tetracyclines. 35 However, and to the best of our knowledge, simultaneous changes in susceptibilities to ciprofloxacin, erythromycin and gentamicin have not been reported previously for RND efflux pumps. An in silico study 36 revealed the presence of 15 putative ATP-binding cassette (ABC) efflux pumps in F. tularensis subsp. tularensis Schu S4, two of which might be involved in drug resistance. The genes encoding these two efflux systems were found in F. tularensis subsp. holarctica LVS, and changes in their regulation or structure may be involved in some of the steps in resistance increase that we detected.
As expected, the evolutionary pathways towards high resistance levels were characterized by parallel genetic changes, with identical codons for gyrA or similar gene regions for gyrB (and to a lesser extent parE) being altered by mutations in independent lineages from the same and even different parental strains (Table 1) . Similarities have also been detected in the order of mutation substitutions in the three independent lineages from F. tularensis LVS. Moreover, the evolution of MIC values followed two main trajectories, one characterized by progressive and low resistance increases, and one by the occurrence of steeper steps of MIC increase. These two types of trajectories may reflect different dynamics of mutation substitution, but also differential fitness effects of the various mutations. Determining the genome sequences of evolved clones at key evolutionary steps would provide valuable information about these dynamics. Besides this parallel evolution, the evolutionary pathways were also characterized by lineage-and/or strain-specific changes. Moreover, a high level of allelic diversity was detected, including mutations that have not been previously related to antibiotic resistance. Except for gyrA, not all type II topoisomerase-encoding genes were modified by mutations in the lineages that derived from all three parental strains. Although this trend may be an artefact related to the small number of independent replicate populations, it may also indicate genetic constraints during evolution in the different genetic backgrounds of the three parental strains.
The evolutionary pathways of the three F. tularensis LVS lineages showed a high level of within-lineage polymorphism, even with our small sampling scheme. Based on phenotypic and genetic data, up to five different types of clones were detected at a single passage (P12 in Fth3). Population dynamics was nicely related to the measured MIC values, as the clones conferring higher resistance levels in previous generations were the final winning genotypes. Therefore, these polymorphic states were not associated with stable co-existence between sub-lineages, but rather reflect clonal interference whereby several sub-lineages can transiently co-exist, each carrying different beneficial mutations until one of them outcompetes the rest of the population owing to further substitution of additional fitness-enhancing mutations. 37 The present study highlighted the evolutionary trajectories towards high levels of fluoroquinolone resistance by target modifications in Francisella species. Our data reveal many different genetic solutions to the acquisition of high-level resistance to fluoroquinolones and even, sometimes, multidrug resistance. This Sutera et al.
diversity of genetic mechanisms and evolutionary trajectories constitutes a general trend in the evolution of antibiotic resistance, 38 although the increase in antibiotic resistance may occur in some cases through a subset of all possible mutational pathways. 14, 39 Although the three analysed species showed differences in mutational profiles, gyrA mutations were pivotal in the evolution of a high resistance level. Therefore, the gyrA codons 83 and 87 can be predicted to be efficient targets for the detection of resistance in clinical Francisella isolates and, more directly, in biological samples. In addition, our experiments revealed new mutations involved in fluoroquinolone resistance in Francisella outside the QRDR that are likely to affect DNA and drug binding. Further investigations are therefore needed to characterize these novel resistance mechanisms. They could unveil new targets for the fast and efficient genetic detection of fluoroquinolone resistance.
